Have a feature idea you'd love to see implemented?
Let us know!
AVTX Avalo Therapeutics Inc
Price (delayed)
$9.65
Market cap
$100.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$19.41
Enterprise value
$18.4M
Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of
Highlights
The company's gross profit has surged by 188% QoQ
Avalo Therapeutics's gross margin has soared by 183% from the previous quarter
Avalo Therapeutics's quick ratio has increased by 41% from the previous quarter but it has decreased by 30% YoY
AVTX's revenue has shrunk by 64% YoY
Key stats
What are the main financial stats of AVTX
Market
Valuations
Earnings
Shares outstanding
10.39M
Market cap
$100.3M
Enterprise value
$18.4M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.47
Price to sales (P/S)
12.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.44
Revenue
$820,000
EBIT
-$10.05M
EBITDA
-$9.91M
Free cash flow
-$36.78M
Per share
Balance sheet
Liquidity
EPS
-$19.41
Free cash flow per share
-$35.56
Book value per share
$20.38
Revenue per share
$0.79
TBVPS
$85.05
Total assets
$98.46M
Total liabilities
$75.72M
Debt
$0
Equity
$21.08M
Working capital
$25.47M
Debt to equity
0
Current ratio
1.42
Quick ratio
1.37
Net debt/EBITDA
8.27
Margins
Efficiency
Dividend
EBITDA margin
-1,208.2%
Gross margin
182%
Net margin
-970.5%
Operating margin
-7,666%
Return on assets
-9.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-26.6%
Return on sales
-1,225.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVTX stock price
How has the Avalo Therapeutics stock price performed over time
Intraday
-11.47%
1 week
-28.41%
1 month
-16.01%
1 year
-55.28%
YTD
6.04%
QTD
1.58%
Financial performance
How have Avalo Therapeutics's revenue and profit performed over time
Revenue
$820,000
Gross profit
$1.49M
Operating income
-$62.86M
Net income
-$7.96M
Gross margin
182%
Net margin
-970.5%
The company's gross profit has surged by 188% QoQ
Avalo Therapeutics's gross margin has soared by 183% from the previous quarter
AVTX's operating income has shrunk by 120% YoY and by 17% QoQ
AVTX's net income has soared by 78% from the previous quarter and by 76% YoY
Growth
What is Avalo Therapeutics's growth rate over time
Valuation
What is Avalo Therapeutics stock price valuation
P/E
N/A
P/B
0.47
P/S
12.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.44
The EPS has soared by 97% YoY and by 59% from the previous quarter
The equity has grown by 43% YoY
AVTX's revenue has shrunk by 64% YoY
The P/S is 39% lower than the 5-year quarterly average of 19.8 but 3.1% higher than the last 4 quarters average of 11.8
Efficiency
How efficient is Avalo Therapeutics business performance
Avalo Therapeutics's ROA has soared by 92% YoY and by 82% from the previous quarter
The ROS has soared by 72% from the previous quarter and by 7% YoY
Dividends
What is AVTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVTX.
Financial health
How did Avalo Therapeutics financials performed over time
AVTX's total assets is 30% greater than its total liabilities
AVTX's current ratio is up by 43% since the previous quarter but it is down by 33% year-on-year
Avalo Therapeutics's quick ratio has increased by 41% from the previous quarter but it has decreased by 30% YoY
The debt is 100% smaller than the equity
The equity has grown by 43% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.